Charlotte G Nyvold[Author] - Search Results

Year	Number of Results
2005	4
2006	4
2007	1
2008	3
2009	3
2011	1
2012	3
2013	5
2014	6
2015	4
2018	1
2019	5
2020	5
2021	6
2022	8
2023	6
2024	3

1

Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease.

Johansen M, Levring MB, Stokbro K, Diaz-delCastillo M, Khan AA, Wickstroem LA, Gundesen MT, Kristensen IB, Nyvold CG, Andersen MØ, Andersen TL, Abildgaard N, Lund T. Johansen M, et al. Cancers (Basel). 2023 Nov 25;15(23):5585. doi: 10.3390/cancers15235585. Cancers (Basel). 2023. PMID: 38067289 Free PMC article. Review.

2

A decade with whole exome sequencing in haematology.

Hansen MC, Haferlach T, Nyvold CG. Hansen MC, et al. Among authors: nyvold cg. Br J Haematol. 2020 Feb;188(3):367-382. doi: 10.1111/bjh.16249. Epub 2019 Oct 10. Br J Haematol. 2020. PMID: 31602633 Free article. Review.

3

Harnessing the Immune System to Fight Multiple Myeloma.

Krejcik J, Barnkob MB, Nyvold CG, Larsen TS, Barington T, Abildgaard N. Krejcik J, et al. Cancers (Basel). 2021 Sep 10;13(18):4546. doi: 10.3390/cancers13184546. Cancers (Basel). 2021. PMID: 34572773 Free PMC article. Review.

4

Mantle cell lymphoma and the evidence of an immature lymphoid component.

Hansen SV, Nyvold CG, Hansen MH. Hansen SV, et al. Leuk Res. 2022 Apr;115:106824. doi: 10.1016/j.leukres.2022.106824. Epub 2022 Mar 9. Leuk Res. 2022. PMID: 35286938 Free article. Review.

5

Investigation of circulating DNA integrity after blood collection.

Cédile O, Veyhe SR, Hansen MH, Titlestad K, Nyvold CG. Cédile O, et al. Biotechniques. 2021 Nov;71(5):550-555. doi: 10.2144/btn-2020-0167. Epub 2021 Oct 14. Biotechniques. 2021. PMID: 34645292 Free article. No abstract available.

6

Perspective: sensitive detection of residual lymphoproliferative disease by NGS and clonal rearrangements-how low can you go?

Hansen MH, Cédile O, Larsen TS, Abildgaard N, Nyvold CG. Hansen MH, et al. Among authors: nyvold cg. Exp Hematol. 2021 Jun;98:14-24. doi: 10.1016/j.exphem.2021.03.005. Epub 2021 Apr 4. Exp Hematol. 2021. PMID: 33823225 Free article. Review.

7

Critical methodological factors in diagnosing minimal residual disease in hematological malignancies using quantitative PCR.

Nyvold CG. Nyvold CG. Expert Rev Mol Diagn. 2015 May;15(5):581-4. doi: 10.1586/14737159.2015.1014341. Epub 2015 Feb 12. Expert Rev Mol Diagn. 2015. PMID: 25676837

8

A highly sensitive and specific qPCR assay for quantification of the biomarker SOX11 in mantle cell lymphoma.

Hamborg KH, Bentzen HH, Grubach L, Hokland P, Nyvold CG. Hamborg KH, et al. Eur J Haematol. 2012 Nov;89(5):385-94. doi: 10.1111/j.1600-0609.2012.01837.x. Epub 2012 Aug 21. Eur J Haematol. 2012. PMID: 22827557 Review.

9

Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation.

Hokland P, Ommen HB, Nyvold CG, Roug AS. Hokland P, et al. Br J Haematol. 2012 Sep;158(5):569-80. doi: 10.1111/j.1365-2141.2012.09203.x. Epub 2012 Jun 28. Br J Haematol. 2012. PMID: 22738609 Free article. Review.

10

Reproducibility of low-level residual myeloma immunoglobulin detection using ultra-deep sequencing.

Cédile O, Hansen MH, Dahlmann SK, Kristensen TK, Abildgaard N, Nyvold CG. Cédile O, et al. Exp Hematol. 2023 Mar-Apr;119-120:14-20. doi: 10.1016/j.exphem.2023.01.002. Epub 2023 Jan 25. Exp Hematol. 2023. PMID: 36708872 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

62 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year